Cellectis S.A. (CLLS) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
vTv Therapeutics (VTVT) has outperformed Cellectis S.A. (CLLS) over the past year, gaining 36.2% versus a loss of 70.9%. Over five years, VTVT leads with a -47.0% price change compared with -88.5% for CLLS. Cellectis S.A. is the larger company by market cap ($126.9 million vs $123.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | VTVT |
|---|---|---|
| Share price | $1.26 | $31.18 |
| Market cap | $126.92M | $123.28M |
| 1-day change | +0.80% | +3.66% |
| YTD return | -74.17% | -22.03% |
| 1-year return | -70.93% | +36.22% |
| 5-year return | -88.46% | -46.97% |
| EPS (TTM) | $-0.64 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $44.00 |
| 52-week low | $1.22 | $19.50 |
| Distance from 52-week high | -77.01% | -29.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +323.02% | +75.47% |
| Average volume | 80.14K | 68.34K |
| Shares outstanding | 72.73M | 3.95M |
| Employees | 224 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTVT has outperformed CLLS by 107.1 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
CLLS vs VTVT FAQ
Which is bigger, Cellectis S.A. or vTv Therapeutics?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $126.92M compared with $123.28M for vTv Therapeutics (VTVT).
Which stock has performed better over the past year, CLLS or VTVT?
VTVT returned +36.22% over the past 12 months, compared with -70.93% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.